On-demand webcast where an expert discusses what advanced practice providers should know about the emerging role of HER2- and TROP2-targeted antibody drug conjugates in NSCLC treatment.
- Provider:Partners for Advancing Clinical Education (PACE)
- Activity Link: https://clinicaloptions.com/activities/oncology/emerging-role-of-adcs-in-nsclc/27944-61093/info
- Start Date: 2024-11-12 06:00:00
- End Date: 2024-11-12 06:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 25000.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 6250.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest